Menu
Home
Forums
Forums
Quick Links
Search Forums
Recent Posts
job listings
catering
whistleblower info
legal help
advertise on CP
submit press release
Menu
Log in
Sign up
Search titles only
Posted by Member:
Separate names with a comma.
Newer Than:
Search this thread only
Search this forum only
Display results as threads
More...
Useful Searches
Recent Posts
Cafepharma Message Boards | Pharma Sales, Device Sales, Lab Sales
Home
Forums
>
Lost Civilizations
>
Allos Therapeutics
>
Wall Street Thinks Folotyn is a bust
>
Reply to Thread
Name:
Verification:
Answer the above question:
(
CustomImgCaptcha
By
Surrey Forum
)
Message:
<p>[QUOTE="Anonymous, post: 3780981"]If you are buying the stock last week, yes. Even a monkey looks like Warren Buffet when you buy at or near a 52 week low. 2009 a week before FOLOTYN was approved no. The stock is down about 50% since we launched the drug. Why? No competition, unmet medical need, global rights to our asset, etc? Its down because we cannot find enough patients to sustain our company. Wall street knows this. Berns knows this (he learned this in april). There is no market for PTCL. Lung might as well be a thousand years away. If your investment horizon is until lung cancer (which will never happen thanks to Alimta) you might make money on the corporate milestones, EMEA application, 30 Million in sales, partner for asia (because NICE will never pay for FOLOTYN in England) etc. but FOLOTYN is a niche drug for a tiny select group of patients. We need all the off label business to sustain the company. We cant meet our current requirements of clinical trials without diluting or partnering. The fuse has been lit, Allos will not exist by June 2011.[/QUOTE]</p><p><br /></p>
[QUOTE="Anonymous, post: 3780981"]If you are buying the stock last week, yes. Even a monkey looks like Warren Buffet when you buy at or near a 52 week low. 2009 a week before FOLOTYN was approved no. The stock is down about 50% since we launched the drug. Why? No competition, unmet medical need, global rights to our asset, etc? Its down because we cannot find enough patients to sustain our company. Wall street knows this. Berns knows this (he learned this in april). There is no market for PTCL. Lung might as well be a thousand years away. If your investment horizon is until lung cancer (which will never happen thanks to Alimta) you might make money on the corporate milestones, EMEA application, 30 Million in sales, partner for asia (because NICE will never pay for FOLOTYN in England) etc. but FOLOTYN is a niche drug for a tiny select group of patients. We need all the off label business to sustain the company. We cant meet our current requirements of clinical trials without diluting or partnering. The fuse has been lit, Allos will not exist by June 2011.[/QUOTE]
Your name or email address:
Do you already have an account?
No, create an account now.
Yes, my password is:
Forgot your password?
Stay logged in
Cafepharma Message Boards | Pharma Sales, Device Sales, Lab Sales
Home
Forums
>
Lost Civilizations
>
Allos Therapeutics
>
Wall Street Thinks Folotyn is a bust
>
Cafepharma Message Boards | Pharma Sales, Device Sales, Lab Sales
Home
Forums
>
Lost Civilizations
>
Allos Therapeutics
>
Wall Street Thinks Folotyn is a bust
>